Utilization of Sacubitril/Valsartan in Real-World Settings

被引：0
|
作者：
Efe Eworuke
Talia J. Menzin
Emily C. Welch
Joy Kolonoski
Ting-Ying Huang
机构：
[1] U.S. Food and Drug Administration,Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research
[2] Harvard Medical School and Harvard Pilgrim Health Care Institute,Department of Population Medicine
来源：
American Journal of Cardiovascular Drugs | 2020年 / 20卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：619 / 623
页数：4
相关论文
共 50 条
  • [31] Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction
    Maria Vincenza Polito
    Angelo Silverio
    Antonella Rispoli
    Gennaro Vitulano
    Federica D’ Auria
    Elena De Angelis
    Francesco Loria
    Alberto Gigantino
    Domenico Bonadies
    Rodolfo Citro
    Albino Carrizzo
    Gennaro Galasso
    Guido Iaccarino
    Carmine Vecchione
    Michele Ciccarelli
    Scientific Reports, 10
  • [32] HEALTH OUTCOMES PROJECTIONS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE IN A REAL-WORLD POPULATION IN PORTUGAL
    Afonso-Silva, M.
    Laires, P. A.
    VALUE IN HEALTH, 2019, 22 : S547 - S548
  • [33] Effects of Sacubitril/Valsartan in real-world HF and reduced ejection fraction (HFrEF) population.
    Polito, M.
    Vitulano, G.
    Rispoli, A.
    D'auria, F.
    Gigantino, A.
    Citro, R.
    Bonadies, D.
    Iaccarino, G.
    Ciccarelli, M. Michele
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 238 - 238
  • [34] Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real-world study
    Wang, Chen
    Lin, Zongwei
    Miao, Dongxia
    Zhang, Hui
    Fu, Kang
    Zhang, Xinyu
    Xiao, Jie
    Hu, Yue
    Sun, Yijun
    Wang, Fen
    Lu, Huixia
    Ji, Xiaoping
    ESC HEART FAILURE, 2023, 10 (03): : 1961 - 1971
  • [35] Five Years of Sacubitril/Valsartan—a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance
    Yee Soo Kim
    Simerjeet Brar
    Natalie D’Albo
    Amit Dey
    Sachin Shah
    Sarju Ganatra
    Sourbha S. Dani
    Cardiovascular Drugs and Therapy, 2022, 36 : 915 - 924
  • [36] Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptions
    Martens, Pieter
    Lambeets, Seppe
    Lau, Chirik Wah
    Dupont, Matthias
    Mullens, Wilfried
    ACTA CARDIOLOGICA, 2019, 74 (02) : 115 - 122
  • [37] SACUBITRIL/VALSARTAN PRESCRIPTION PATTERNS AND TITRATION IN A REAL-WORLD SETTING IN PORTUGAL: AN ANALYSIS OF THE PRIME STUDY
    Afonso-Silva, M.
    Laires, P. A.
    Cary, M.
    Guerreiro, J. P.
    Romao, M.
    Teixeira Rodrigues, A.
    VALUE IN HEALTH, 2019, 22 : S568 - S568
  • [38] Updated insights on dementia-related risk of sacubitril/valsartan: A real-world pharmacovigilance analysis
    Chen, Congqin
    Ding, Lingqing
    Fu, Fang
    Xiao, Jie
    CNS NEUROSCIENCE & THERAPEUTICS, 2023, 29 (09) : 2548 - 2554
  • [39] Effectiveness and Safety of Sacubitril/Valsartan in Patients with Chronic Kidney Disease-A Real-World Experience
    Pereira, Sara C.
    Rodrigues, Tiago
    Nunes-Ferreira, Afonso
    Agostinho, Joao R.
    Pinto, Fausto J.
    Brito, Dulce
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (04)
  • [40] Beneficial Effects of Sacubitril/Valsartan at Low Doses in an Asian Real-World Heart Failure Population
    Hu, Jingwen
    Wu, Yucheng
    Zhou, Xiujuan
    Wang, Xiaozhi
    Jiang, Wanying
    Huo, Junyu
    Shan, Qijun
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2020, 76 (04) : 445 - 451
12345